Novo Nordisk's $1.3 Billion Kidney Bet Just Went to Zero

And on paper, the strategy looks reasonable. Novo has been expanding around its metabolic core with acquisitions, partnerships, and clinical bets in adjacent areas like cardiovascular disease, kidney disease, liver disease, and rare blood disorders. They bought Akero Therapeutics for its MASH (fatty liver disease) drug. They partnered with Amazon Web Services on AI-driven drug discovery. They inked a deal with Vivtex for next-generation oral biologic delivery.

But acquisitions and partnerships are just tickets to the game. You still have to win the trials. And right now, Novo is 0-for-2 in its biggest attempts to build franchises outside obesity and diabetes.

It's like a basketball team with one superstar trying to build a supporting cast through trades, only to watch every new pickup get injured in preseason.

A Crowded Field That Won't Wait

The CKD drug development landscape isn't going to pause while Novo figures things out. If anything, it's accelerating.

Bayer's finerenone already has approval for CKD in diabetic patients and is pushing into non-diabetic kidney disease through new Phase 3 trials. The FDA even granted it Priority Review in 2026 for an expanded indication covering type 1 diabetes and CKD.

AstraZeneca is running multiple late-stage CKD programs that combine its blockbuster SGLT2 inhibitor dapagliflozin with newer agents like zibotentan (targeting the endothelin pathway) and baxdrostat (targeting aldosterone). Boehringer Ingelheim has a large Phase 3 trial pairing its own SGLT2 inhibitor empagliflozin with the aldosterone synthase inhibitor BI 690517. Vertex is going after a genetically defined subset of kidney disease with inaxaplin.

The trend is clear: the field is moving toward combination therapies and genetically targeted approaches. Novo's ocedurenone, a standalone mineralocorticoid receptor antagonist, was already competing in Bayer's backyard. Now it's not competing at all.

Wall Street Isn't Exactly Cheering

Analyst sentiment on Novo Nordisk heading into September 2026 was already lukewarm before this latest cancellation. The consensus rating sits at Hold, with price targets clustered near the current share price rather than pointing to meaningful upside.

The concerns are piling up like dishes in a college apartment sink. Pipeline setbacks with ziltivekimab and CagriSema (Novo's next-gen obesity combo) have dented confidence. Rising competition from Eli Lilly is squeezing market share expectations. U.S. pricing headwinds for obesity drugs are pressuring revenue forecasts.

Multiple analysts now characterize Novo as a "wait-for-catalysts" story rather than a recovery trade. Nobody's predicting a collapse, but nobody's pounding the table either. The stock is stuck in a credibility gap: investors need to see wins, and the pipeline keeps delivering losses.

What's Left in the Tank?

Novo isn't out of cards to play. The company still has several potentially important readouts ahead.

Its MASH program (via the Akero acquisition of efruxifermin) is in Phase 3 and represents a genuine diversification opportunity in metabolic liver disease. The two remaining ziltivekimab trials could still deliver positive data, though expectations are appropriately tempered after ZEUS. And Novo's core obesity and diabetes pipeline, including amycretin and oral semaglutide formulations, continues to advance.

The hemophilia A drug denecimig (Mim8) is currently under FDA review, and coramitug is in Phase 3 for a form of heart disease called ATTR cardiomyopathy. These aren't blockbuster-scale bets on their own, but they contribute to the narrative that Novo can win outside its comfort zone.

The Bigger Picture

Two failed trials don't make a company a failure. Novo Nordisk still sits on one of the most valuable franchises in pharmaceutical history with its GLP-1 portfolio. Semaglutide isn't going anywhere.

But the ocedurenone cancellation, coming on the heels of the ziltivekimab disappointment, crystallizes a question that investors have been asking with increasing urgency: can Novo Nordisk build its next act, or is it a one-franchise company riding a very expensive wave?

The next 12 months of data readouts will go a long way toward answering that. For now, the scoreboard outside of obesity and diabetes reads: Novo 0, Clinical Reality 2.